Reference | 1: Allegra S, Cusato J, De Francia S, Arduino A, Longo F, Pirro E, Massano D, De
Nicolò A, Piga A, D/’Avolio A. Role of CYP24A1, VDR and GC gene polymorphisms on
deferasirox pharmacokinetics and clinical outcomes. Pharmacogenomics J. 2017 Nov
21. doi: 10.1038/tpj.2017.43. [Epub ahead of print] PubMed PMID: 29160302.
<br>
2: Yesilipek MA, Karasu G, Kaya Z, Kuskonmaz BB, Uygun V, Dag I, Ozudogru O,
Ertem M. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and
Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children
with Β-Thalassemia Major. Biol Blood Marrow Transplant. 2017 Nov 16. pii:
S1083-8791(17)30820-0. doi: 10.1016/j.bbmt.2017.11.006. [Epub ahead of print]
PubMed PMID: 29155313.
<br>
3: Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Piga A,
D/’Avolio A. Effect of pharmacogenetic markers of vitamin D pathway on deferasirox
pharmacokinetics in children. Pharmacogenet Genomics. 2017 Nov 2. doi:
10.1097/FPC.0000000000000315. [Epub ahead of print] PubMed PMID: 29099735.
<br>
4: Lescano MA, Tavares LC, Santos PCJL. Juvenile hemochromatosis: HAMP mutation
and severe iron overload treated with phlebotomies and deferasirox. World J Clin
Cases. 2017 Oct 16;5(10):381-383. doi: 10.12998/wjcc.v5.i10.381. PubMed PMID:
29085829; PubMed Central PMCID: PMC5649000.
<br>
5: Salehi S, Saljooghi AS, Badiee S, Moqadam MM. Chelation of Thallium (III) in
Rats Using Combined Deferasirox and Deferiprone Therapy. Toxicol Res. 2017
Oct;33(4):299-304. doi: 10.5487/TR.2017.33.4.299. Epub 2015 Oct 15. PubMed PMID:
29071014; PubMed Central PMCID: PMC5654193.
<br>
6: Shen JC, Zhang YC, Zhao MF. Protective effects of deferasirox and
N-acetyl-L-cysteine on iron overload-injured bone marrow. Braz J Med Biol Res.
2017 Oct 19;50(12):e6087. doi: 10.1590/1414-431X20176087. PubMed PMID: 29069221;
PubMed Central PMCID: PMC5649863.
<br>
7: Osborne V, Davies M, Layton D, Shakir SAW. Utilisation and Safety of
Deferasirox: Results from an Observational Cohort Study in England. Drug Saf.
2017 Oct 10. doi: 10.1007/s40264-017-0606-2. [Epub ahead of print] PubMed PMID:
29019038.
<br>
8: Maximova N, Gregori M, Simeone R, Sonzogni A, Boz G, Fucile C, Marini V,
Martelli A, Mattioli F. Safety and tolerability of deferasirox in pediatric
hematopoietic stem cell transplant recipients: one facility/’s five years/’
experience of chelation treatment. Oncotarget. 2017 Jun 28;8(38):63177-63186.
doi: 10.18632/oncotarget.18725. eCollection 2017 Sep 8. PubMed PMID: 28968980;
PubMed Central PMCID: PMC5609912.
<br>
9: Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. Comparison of
iron chelation effects of deferoxamine, deferasirox, and combination of
deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.
Caspian J Intern Med. 2017 Summer;8(3):159-164. doi: 10.22088/cjim.8.3.159.
PubMed PMID: 28932366; PubMed Central PMCID: PMC5596185.
<br>
10: Thakor DR, Desai CK, Kapadia JD, Dikshit RK, Mehariya KM. Efficacy and Safety
of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching
Hospital. Indian J Med Paediatr Oncol. 2017 Apr-Jun;38(2):103-110. doi:
10.4103/ijmpo.ijmpo_103_16. PubMed PMID: 28900315; PubMed Central PMCID:
PMC5582544.
|